by Bioblast Editor | Sep 1, 2020 | Biosimilars updates
NeuClone Pharmaceuticals disclosed it is working on biosimilars referencing Opdivo® (nivolumab) and Keytruda® (pembrolizumab). The products are in the advanced stages of pre-clinical development and are being developed in partnership with the Serum Institute of...
